<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101235745</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32213</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Med Genet C Semin Med Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Am J Med Genet C Semin Med Genet</journal-id>
<journal-title-group>
<journal-title>American journal of medical genetics. Part C, Seminars in medical genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4868</issn>
<issn pub-type="epub">1552-4876</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27860216</article-id>
<article-id pub-id-type="pmc">5592089</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.c.31531</article-id>
<article-id pub-id-type="manuscript">NIHMS902445</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Somatic Overgrowth Disorders of the PI3K/AKT/mTOR Pathway &amp; Therapeutic Strategies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Keppler-Noreuil</surname>
<given-names>Kim M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parker</surname>
<given-names>Victoria E.R.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Darling</surname>
<given-names>Thomas N.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Martinez-Agosto</surname>
<given-names>Julian A.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>National Human Genome Research institute, National Institutes of Health, Bethesda, Maryland</aff>
<aff id="A2">
<label>2</label>The University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Cambridge, UK</aff>
<aff id="A3">
<label>3</label>Department of Dermatology, Uniformed Services University of Health Sciences, Bethesda, Maryland</aff>
<aff id="A4">
<label>4</label>Department of Human Genetics, Division of Medical Genetics, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence to: Kim M. Keppler-Noreuil, M.D., National Human Genome Research Institute/NIH, 49 Convent Drive 4A83, Bethesda, MD 20892. <email>kim.keppler-noreuil@nih.gov</email>, Tel: 301-275-7985, FAX: 301-402-2170</corresp>
<fn fn-type="COI-statement" id="FN2">
<p>The authors have no conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>18</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>172</volume>
<issue>4</issue>
<fpage>402</fpage>
<lpage>421</lpage>
<!--elocation-id from pubmed: 10.1002/ajmg.c.31531-->
<abstract>
<p id="P1">The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway plays an essential role in regulation of normal cell growth, metabolism, and survival. Somatic activating mutations in the PI3K/AKT/mTOR pathway are amongst the most common mutations identified in cancer, and have been shown to cause a spectrum of overgrowth syndromes including PIK3CA-Related Overgrowth Spectrum, Proteus syndrome, and brain overgrowth conditions. Clinical findings in these disorders may be isolated or multiple, including sporadic or mosaic overgrowth (adipose, skeletal, muscle, brain, vascular, or lymphatic), and skin abnormalities (including epidermal nevi, hyper- and hypopigmented lesions), and have the potential risk of tumorigenesis. Key negative regulators of the PI3K-AKT signaling pathway include PTEN and TSC1/TSC2 and germline loss-of function mutations of these genes are established to cause PTEN Hamartoma Tumor Syndrome and Tuberous Sclerosis Complex. Mosaic forms of these conditions lead to increased activation of PI3K and mTOR at affected sites and there is phenotypic overlap between these conditions. All are associated with significant morbidity with limited options for treatment other than symptomatic therapies and surgeries. As dysregulation of the PI3K/AKT/mTOR pathway has been implicated in cancer, several small molecule inhibitors targeting different components of the PI3K/AKT/mTOR signaling pathway are under clinical investigation. The development of these therapies brings closer the prospect of targeting treatment for somatic PI3K/AKT/mTOR-related overgrowth syndromes. This review describes the clinical findings, gene function and pathogenesis of these mosaic overgrowth syndromes, and presents existing and future treatment strategies to reduce or prevent associated complications of these disorders.</p>
</abstract>
<kwd-group>
<kwd>Somatic mosaicism</kwd>
<kwd>segmental overgrowth</kwd>
<kwd>therapy</kwd>
<kwd>PI3K/AKT/mTOR pathway</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>